According to Warden, this capital will contribute to the development of the platform’s cutting-edge wallet, along with expanding its agentic functionalities.According to Warden, this capital will contribute to the development of the platform’s cutting-edge wallet, along with expanding its agentic functionalities.

Warden Obtains $4 Million Funding at $200M Total Valuation to Drive Agentic Internet

money safe 6

Warden, a well-known Web3 infrastructure entity, has announced the successful completion of a strategic funding round of $4M. At the valuation of $200M, this strategic funding permits Warden to accelerate agentic internet. As Warden revealed in its official press release, dissimilar to conventional venture capital funding rounds, this raise was accomplished without any traditional fundraising procedure or VC roadshow. Additionally, this event has brought together partners and builders, reinforcing the platform’s mission of advancing the agent economy.

Warden Accomplishes Strategic Funding of $4M to Accelerate Agentic Internet

Warden’s latest strategic funding of $4M at the cumulative $200M valuation significantly contributes to its efforts for the agentic internet. In this respect, the round included well-known partners like Venice.AI, Messari, and 0G Labs. As per Warden, the respective contributors are more than passive investors while working as active builders and shipping products, along with solving mutual challenges.

In addition to this, this approach highlights Warden’s stance against the conventional VC-driven growth model, supporting instead comprehensive technical and operational alignment. While discussing this move, Warden’s CEO, Josh Goodbody, stressed that the funding round occurred organically via existing relationships instead of a formal capital-raising endeavor. As per him,  the key element uniting participants was the mutual understanding of real-world problems and long-term goals. As a result, the development will enhance product quality and flexibility while fulfilling long-term objectives.

Eyeing Next Growth Phase, Prioritizing Solutions to Developer Challenges

According to Warden, the latest capital will contribute to the further development of the platform’s cutting-edge wallet, along with expanding its agentic functionalities. The partners also echoed confidence in the ongoing endeavors of Warden. So, while looking ahead, the platform remains confident to address challenges dealing with developer experience, clarity, and reliability.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26